Understanding and managing methotrexate nephrotoxicity

Oncologist

Volumn 11, Issue 6, 2006, Pages 694-703

  Widemann, Brigitte C ^a   Adamson, Peter C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Carboxypeptidase G2; Hemodialysis Hemoperfusion; High dose chemotherapy; Methotrexate toxicity; Renal dysfunction; Rescue agents; Thymidine

Indexed keywords

FOLINIC ACID; GLUCARPIDASE; METHOTREXATE; RECOMBINANT ENZYME; THYMIDINE; UNCLASSIFIED DRUG;

ALKALINIZATION; DRUG EFFICACY; HUMAN; INCIDENCE; KIDNEY INJURY; MORTALITY; NEPHROTOXICITY; PATHOGENESIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; GAMMA-GLUTAMYL HYDROLASE; HUMANS; KIDNEY FAILURE; LEUCOVORIN; METHOTREXATE; NEOPLASMS; RENAL INSUFFICIENCY;

EID: 33745647522     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-6-694     Document Type: Review

References (79)

1. Allegra CJ. Antifolates. In: Chabner BA, Collins JM, eds. Cancer Chemotherapy. Philadelphia: Lippincott Company, 1990:110-153.
2. Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 1977;4:87-101.
3. Djerassi I. High-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) rescue: background and rationale. Cancer Chemother Rep 1975;6:3-6.
4. Jolivet J, Cowan KH, Curt GA et al. The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309:1094-1104.
5. Albertioni F, Flato B, Seideman P et al. Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol 1995;47:507-511.
6. Bright RD. Methotrexate in the treatment of psoriasis. Cutis 1999;64:332-334.
7. Balis FM, Savitch JL, Bleyer WA et al. Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 1985;3:485-489.
8. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987;5:2017-2031.
9. Frei E 3rd, Blum RH, Pitman SW et al. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 1980;68:370-376.
10. Djerassi I. Methotrexate infusions and intensive supportive care in the management of children with acute lymphocytic leukemia: follow-up report. Cancer Res 1967;27:2561-2564.
11. Yap HY, Blumenschein GR, Yap BS et al. High-dose methotrexate for advanced breast cancer. Cancer Treat Rep 1979;63:757-761.
12. Stoller RG, Hande KR, Jacobs SA et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977;297:630-634.
13. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978;41:36-51.
14. Abelson HT, Fosburg MT, Beardsley GP et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983;1:208-216.
15. Stark AN, Jackson G, Carey PJ et al. Severe renal toxicity due to intermediate-dose methotrexate. Cancer Chemother Pharmacol 1989;24:243-245.
16. Djerassi I, Kim JS, Nayak NP et al. High-dose methotrexate with citrovorum factor rescue: a new approach to cancer chemotherapy. Recent advances in cancer treatment. Tagnon HJ, Staquet MJ, ed. New York: Raven Press, Monograph Series of the European Organization for Research on Treatment of Cancer 1977;3:3-6.
17. Messmann R, Allegra C. Antifolates. In Chabner B, Longo D, eds. Cancer Chemotherapy and Biotherapy. Philadelphia: Lippincott Williams & Wilkins, 2001:139-184.
18. Chabner BA, Allegra CJ, Curt GA et al. Polyglutamation of methotrexate: Is methotrexate a prodrug? J Clin Invest 1985;76:907-912.
19. Allegra CJ, Chabner BA, Drake JC et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985;260:9720-9726.
20. Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 1973;52:1804-1811.
21. Jacobs SA, Stoller RG, Chabner BA et al. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 1976;57:534-538.
22. Lankelma J, van der Klein E, Ramaekers F. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett 1980;9:133-142.
23. Sholar PW, Baram J, Seither R et al. Inhibition of folate-dependent enzymes by 7-OH-methotrexate. Biochem Pharmacol 1988;37:3531-3534.
24. Donehower RC, Hande KR, Drake JC et al. Presence of 2,4-diamino-N10- methylpteroic acid after high-dose methotrexate. Clin Pharmacol Ther 1979;26:63-72.
25. 10-methylpteroic acid. J Pharmacol Exp Ther 2000;294:894-901.
26. Widemann BC, Balis FM, Adamson PC. Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader. Clin Chem 1999;45:223-228.
27. Smeland E, Fuskevåg OM, Nymann K et al. High-dose 7-hydroxymethotrexate: acute toxicity and lethality in a rat model. Cancer Chemother Pharmacol 1996;37:415-422.
28. Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet 1986;11:223-235.
29. Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J Rheumatol 1991;18:609-610.
30. Cassano WF. Serious methotrexate toxicity caused by interaction with ibuprofen. Am J Pediatr Hematol Oncol 1989;11:481-482.
31. Furst DE, Herman RA, Koehnke R et al. Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 1990;79:782-786.
32. Lawrenz-Wolf B, Wolfrom C, Frickel C et al. [Severe renal impairment of methotrexate elimination after high dose therapy]. Klin Padiatr 1994;206:319-326. German.
33. Relling MV, Fairclough D, Ayers D et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994;12:1667-1672.
34. 2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 1997;15:2125-2134.
35. Von Hoff DD, Penta JS, Helman LJ et al. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep 1977;61:745-748.
36. Chan H, Evans WE, Pratt CB. Recovery from toxicity associated with high-dose methotrexate: prognostic factors. Cancer Treat Rep 1977;61:797-804.
37. Jaffe N, Traggis D. Toxicity of high-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) in osteogenic sarcoma. Cancer Chemother Rep 1975;6:31-36.
38. Bleyer WA. Therapeutic drug monitoring of methotrexate and other anti-neoplastic drugs. In: Baer DM, Dita WR, eds. Interpretations in Therapeutic Drug Monitoring. Chicago,: American Society of Clinical Pathology, 1981:169-181.
39. Takami M, Kuniyoshi Y, Oomukai T et al. Severe complications after high-dose methotrexate treatment. Acta Oncol 1995;34:611-612.
40. Jürgens H, Beron G, Winkler K. Toxicity associated with combination chemotherapy for osteosarcoma: a report of the cooperative osteosarcoma study (COSS 80). J Cancer Res Clin Oncol 1983;106(suppl):14-18.
41. Haim N, Kedar A, Robinson E. Methotrexate-related deaths in patients previously treated with cis-diamminedichloride platinum. Cancer Chemother Pharmacol 1984;13:223-225.
42. Widemann BC, Balis FM, Kempf-Bielack B et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004;100:2222-2232.
43. Hoang-Xuan K, Taillandier L, Chinot O et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003;21:2726-2731.
44. Hande KR, Balow JE, Drake JC et al. Methotrexate and hemodialysis [letter]. Ann Intern Med 1977;87:495-496.
45. Ahmad S, Shen FH, Bleyer WA. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. Arch Intern Med 1978;138:1146-1147.
46. Djerassi I, Ciesielka W, Kim JS. Removal of methotrexate by filtration-adsorption using charcoal filters or by hemodialysis. Cancer Treat Rep 1977;61:751-752.
47. Wall SM, Johansen MJ, Molony DA et al. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis 1996;28:846-854.
48. Saland JM, Leavey PJ, Bash RO et al. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol 2002;17:825-829.
49. Gibson TP, Reich SD, Krumlovsky FA et al. Hemoperfusion for methotrexate removal. Clin Pharmacol Ther 1977;23:351-355.
50. Greil J, Wyss PA, Ludwig K et al. Continuous plasma resin perfusion for detoxification of methotrexate. Eur J Pediatr 1997;156:533-536.
51. Bouffet E, Frappaz D, Laville M et al. Charcoal haemoperfusion and methotrexate toxicity. Lancet 1986;1:1497.
52. Relling MV, Stapleton FB, Ochs J et al. Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer 1988;62:884-888.
53. Kawabata K, Makino H, Nagake Y et al. A case of methotrexate-induced acute renal failure successfully treated with plasma perfusion and sequential hemodialysis. Nephron 1995;71:233-234.
54. Jambou P, Levraut J, Favier C et al. Removal of methotrexate by continuous venovenous hemodiafiltration. Contrib Nephrol 1995;116:48-52.
55. Grimes DJ, Bowles MR, Buttsworth JA et al. Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma. Drug Saf 1990;5:447-454.
56. Frappaz D, Bouffet E, Biron P et al. [Methotrexate poisoning: value of exchange transfusion]. Pediatrie 1987;42:257-260. French.
57. Howell SB, Herbst K, Boss GR et al. Thymidine requirements for the rescue of patients treated with high-dose methotrexate. Cancer Res 1980;40:1824-1829.
58. Grem JL, King SA, Sorensen JM et al. Clinical use of thymidine as a rescue agent from methotrexate toxicity. Invest New Drugs 1991;9:281-290.
59. Ensminger WD, Frei E 3rd. The prevention of methotrexate toxicity by thymidine infusions in humans. Cancer Res 1977;37:1857-1863.
60. Albrecht AM, Boldizsar E, Hutchison DJ. Carboxypeptidase displaying differential velocity in hydrolysis of methotrexate, 5-methyltetrahydrofolic acid, and leucovorin. J Bacteriol 1978;134:506-513.
61. McCullough JL, Chabner BA, Bertino JR. Purification and properties of carboxypeptidase G 1. J Biol Chem 1974;246:7207-7213.
62. Chabner BA, Johns DG, Bertino JR. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature 1972;239:395-397.
63. 1 - a selective approach to the therapy of central nervous system tumors. In: Kisliuk RL, Brown GM, eds. Chemistry and Biology of Pteridines. New York: Elsevier North Holland, Inc., 1979:629-633.
64. Abelson HT, Kufe DW, Skarin AT et al. Treatment of central nervous system tumors with methotrexate. Cancer Treat Rep 1981;65(suppl 1):137-140.
65. 2 in rhesus monkeys. J Clin Oncol 1992;10:1359-1364.
66. 2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem 1985;148:447-453.
67. 2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol 1983;156:1222-1227.
68. Widemann BC, Hetherington ML, Murphy RF et al. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer 1995;76:521-526.
69. 2) and leucovorin (LV) rescue with and without addition of thymidine (Thd) for high-dose methotrexate (HDMTX) induced renal dysfunction Proc Am Soc Clin Oncol 2005;23:153s.
70. Buchen S, Ngampolo D, Melton RG et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 2005;92:480-487.
71. 2) and leucovorin (LV) for patients with high-dose methotrexate (HDMTX) induced renal failure. Proc Am Soc Clin Oncol 1998;17:222a.
72. 2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications. Cancer Chemother Pharmacol 2005;55:347-353.
73. Pinedo HM, Zaharko DS, Bull JM et al. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 1976;36:4418-4424.
74. Flombaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol 1999;17:1589-1594.
75. Tattersall M, Parker L, Pitman S et al. Clinical pharmacology of high-dose methotrexate (NSC-740). Cancer Chemother Rep 1975;6:25-29.
76. Pitman SW, Parker LM, Tattersall MH et al. Clinical trial of high-dose methotrexate (NSC-740) with citrovorum factor (NSC-3590)-toxicologic and therapeutic observations. Cancer Chemother Rep 1975;6:43-49.
77. Nirenberg A, Mosende C, Mehta BM et al. High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep 1977;61:779-783.
78. Isacoff WH, Eilber F, Tabbarah H et al. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue. Cancer Treat Rep 1978;62:1295-1304.
79. Evans WE, Pratt CB, Taylor RH et al. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 1979;3:161-166.